Psychedelic Pionee | Compass Pathways leads the charge in developing psilocybin-based therapy COMP360 for treatment-resistant depression, navigating clinical trials and regulatory hurdles |
Market Potential | Analysts project peak revenues of $2.3 billion for COMP360, with a potential market exceeding $1 billion in treatment-resistant depression alone |
Regulatory Landscape | Explore how Compass Pathways' methodical approach aligns with FDA guidance, potentially expediting approval in an evolving regulatory environment for psychedelic therapies |
Financial Outlook | With analyst price targets ranging from $12 to $60, Compass Pathways faces challenges but maintains a strong liquidity position as it advances towards commercialization |
Metrics to compare | CMPS | Sector Sector - Average of metrics from a broad group of related sector companies | Relationship RelationshipCMPSPeersSector | |
|---|---|---|---|---|
P/E Ratio | −8.2x | −2.8x | −0.5x | |
PEG Ratio | −1.19 | 0.07 | 0.00 | |
Price/Book | 4.5x | 3.8x | 2.6x | |
Price / LTM Sales | - | 5.5x | 3.1x | |
Upside (Analyst Target) | 77.2% | 174.0% | 54.0% | |
Fair Value Upside | Unlock | 10.9% | 6.5% | Unlock |